THX Pharma

THX Pharma is a clinical-stage pharmaceutical company focused on the development of innovative cannabinoid-based therapies for central nervous system (CNS) disorders and other unmet medical needs. The company utilizes a unique approach that leverages the 'entourage effect,' combining cannabinoids with other FDA-approved drugs to improve therapeutic outcomes and safety profiles. Its lead programs, THX-111 and THX-112, target Tourette Syndrome and Obstructive Sleep Apnea, respectively, and have both reached Phase 2 clinical development. THX Pharma aims to repurpose existing compounds to address significant unmet needs in neurology and sleep medicine. The company operates as a specialized entity within the SciSparc (formerly Therapix Biosciences) corporate structure. By focusing on combination therapies, THX Pharma seeks to reduce the dosage of cannabinoids required, thereby minimizing psychoactive side effects while maintaining efficacy.